Search Bar & Filters
Found 25 Actively Recruiting clinical trials
Actively Recruiting
Researchers are monitoring the use of the Virtue4 Male Sling System in men with stress urinary incontinence following prostate surgery. This observational study aims to collect medical data on the devices effectiveness and safety over 12 and 36 months after implantation. The study is conducted in multiple centers across Europe and focuses on real-world use by experienced urologists. The Virtue4 Male Sling is an implantable device made of polypropylene mesh designed to support the urethra and help manage urinary incontinence caused by intrinsic sphincter deficiency. This study involves men who have already received the sling during routine clinical care. Follow-up includes visits at baseline before implantation, between 1 and 3 months post-operation, and at 12 months, with additional annual questionnaires sent out at 24 and 36 months. Participants will undergo routine clinical assessments, including questionnaires about their urinary symptoms and quality of life, pad weight testing, uroflowmetry, and measurement of urine remaining after voiding at several points during the study. Researchers will monitor patient-reported improvement and any adverse events at 12 months. The study extends to 36 months with ongoing questionnaires to track long-term outcomes and satisfaction. Participation involves regular clinical visits and mailed surveys over three years.
Actively Recruiting
Malignant hypertension is a very serious form of high blood pressure that can be fatal if untreated. This research aims to create the first large, multicenter database to better understand this disease, including its modern epidemiology, how patients are currently managed, and the diseases diagnostic criteria. The study will help improve knowledge and may lead to new treatment trials and evidence-based recommendations. The study is an observational registry enrolling patients diagnosed with malignant hypertension based on classic definitions, including severe blood pressure elevation and organ damage. It plans to recruit 500 patients and follow them for five years to study their prognosis and the impact of different patient characteristics and organ involvement. By collecting detailed data on disease features and care pathways, the study hopes to update definitions and management approaches. Participants will be observed over five years, with researchers collecting information on their health status, organ damage, and treatment. The main outcome measured is the five-year prognosis of patients. This long-term follow-up will provide detailed knowledge about the disease course and help identify factors influencing outcomes, without any study treatments or interventions being assigned.
Actively Recruiting
Researchers are evaluating the real-world effectiveness of deucravacitinib in adults diagnosed with moderate-to-severe plaque psoriasis. This observational study aims to understand how this treatment works outside of controlled clinical trials, focusing on health outcomes important to patients and doctors. It is sponsored by Bristol-Myers Squibb and conducted in France. Participants in this study have started treatment with deucravacitinib as prescribed by their doctors. The study observes these patients over time without altering their treatment plans. There are no placebo or comparison groups since this is an observational study that follows patients initiating deucravacitinib treatment. During the study, doctors will assess skin condition using the Physicians Global Assessment and measure quality of life with the Dermatology Life Quality Index at baseline and several points up to 24 months. Patients will also report symptoms like itch, skin pain, and fatigue using visual scales. Researchers will track how long patients remain on treatment and reasons for stopping. The study involves regular follow-ups at months 1, 4, 12, 18 optional, and 24 to gather this information.
Actively Recruiting
Researchers are evaluating the safety and effects of Abrocitinib in adults with moderate to severe atopic dermatitis, a long-lasting skin condition that causes inflammation, redness, and irritation. This observational study aims to understand how Abrocitinib works in real-life clinical settings for patients aged 18 and older who do not have other medical conditions that would prevent them from taking the medication. All participants will take Abrocitinib as a daily tablet and may also use medicated topical treatments for their condition. The study lasts 24 months, during which participants will be monitored regularly. They will visit the study clinic approximately five times, about once every 4 to 6 months, to report their experiences and health status while using the medication. Throughout the study, researchers will assess participants using various measures such as skin condition scores, itching severity scales, and sleep quality assessments. They will also track treatment adherence, any changes in medication dosage, and any side effects. The main outcome focuses on the proportion of patients achieving clear or almost clear skin after 16 weeks, with ongoing evaluations through 24 months to monitor safety and effectiveness.
Actively Recruiting
Researchers are investigating treatments for metastatic clear cell renal cell carcinoma RCC, a type of kidney cancer. The study compares two combination therapies one using two immune checkpoint inhibitors ICI-ICI and the other combining an immune checkpoint inhibitor with a vascular endothelial growth factor receptor tyrosine kinase inhibitor ICI-VEGFR TKI. The goal is to determine which approach better improves overall survival and progression-free survival based on PD-L1 biomarker status, addressing the current lack of direct comparison between these treatments. Participants will receive one of two treatment plans. One group will get nivolumab and ipilimumab infusions every three weeks, followed by maintenance nivolumab for up to two years. The other group receives an investigators choice among three combinations axitinib plus pembrolizumab, cabozantinib plus nivolumab, or lenvatinib plus pembrolizumab. Oral and intravenous medications are administered at specified doses and schedules, with treatment continued until progression, unacceptable side effects, or two years of therapy. During the study, participants will undergo evaluations including survival tracking, tumor response assessments, and quality of life questionnaires at regular intervals. Researchers will also monitor treatment duration, adverse events, health economics, and collect biological samples for future research. The study plans to enroll 1,250 patients over four years across multiple European countries, with a total follow-up period extending up to 97 months to assess long-term outcomes.
Actively Recruiting
Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Researchers are investigating treatments for patients with hormone receptor-positive, HER2 low or ultralow metastatic breast cancer who are undergoing first-line therapy with a CDK46 inhibitor combined with an aromatase inhibitor or fulvestrant. This open-label, multicenter phase II study focuses on patients whose tumor DNA remains detectable in their blood after four weeks of standard therapy, aiming to evaluate progression-free survival using trastuzumab deruxtecan T-DXd treatment. Patients first enter a screening phase to confirm the presence of circulating tumor DNA after starting standard treatment. Those with persistent tumor DNA are enrolled in the treatment phase, where they receive trastuzumab deruxtecan as an intravenous injection every three weeks at a dose of 5.4 mgkg. This single-group study evaluates how long patients live without disease progression while receiving the study drug. Participants undergo regular assessments including laboratory tests and imaging to monitor their disease status and safety during the study. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, clinical benefit, time to response, and treatment toxicity up to five years. Participants are followed for outcomes and safety throughout the study period, which may last several years.
Actively Recruiting
Researchers are gathering and storing biological samples from patients with malignant hypertension, a severe and sudden form of high blood pressure that can quickly damage organs and be fatal if untreated. This observational study collects samples to better understand the diseases causes, identify new markers, and find potential treatment targets. The study includes patients from the HAMA cohort and covers various disease types. Samples are collected at two points newly diagnosed patients provide samples during the acute phase within 7 days of admission and again during a follow-up visit between 1 and 6 months. Pre-existing patients in the cohort may have a one-time genetic sample collected. Samples include serum, plasma, urine, blood DNA, and blood RNA, all stored under quality conditions. Participants undergo clinical and biological evaluations at diagnosis and during follow-up visits scheduled at 1, 3, 6, and 12 months, then annually for five years. Researchers monitor disease mechanisms, organ damage, and immune system involvement by linking sample analysis with patient data. This long-term follow-up helps decipher malignant hypertension progression and target organ damage development.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
1-10 of 25
1